VirnetX RECEIVING Apple Code and 4 Stock Analyses Not to Miss

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Quest Diagnostics Inc. (NYSE:DGX): According to Morgan Stanley, Merck’s (NYSE:MRK) osteoporosis drug Odanacatib’s positive trial results is also beneficial for Quest, but share strength is overdone. The firm gives an Equal Weight rating.

Don’t Miss: Are Apple’s MacBook Pro Shipping Delays FINALLY Improving?

Noble Corp. (NYSE:NE) had its price target increased by Susquehanna due to higher than expected dayrates on two jackup rigs and several new contracts included int its newest fleet status report. The shares are given a Positive rating.

The Scotts Miracle-Gro Co. (NYSE:SMG) FY12 and FY13 estimates were reduced by Oppenheimer because of the current drought conditions prevalent through much of the U.S. the firm claims it would wait for shares to bottom out before becoming more constructive. The firm gives the shares a Perform rating.

VirnetX Holding Corp (AMEX:VHC): According to Cowen, a Texas court in the Markman hearing has ordered  Apple (NASDAQ:AAPL) to let its engineers depostion and reveal the source code to VirnetX (AMEX:VHC) next Tuesday by 5 pm. Cowen also stated that Apple needs to decide where to settle with Virnex soon or to continue with a trial which continues to reveal more information. Shares have an Outperform rating.

Vertex Pharmaceuticals Incorporated’s (NASDAQ:VRTX) cystic fibrosis potential is important, but it is too early to count the company out of the race for hepatitis C treatment. The firm views that recent pullback in Vertex shares as a buying opportunity.

Don’t Miss: Apple: Crossing Borders and Breaking Sanctions.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business